Last reviewed · How we verify
Oseltamivir 7 days
At a glance
| Generic name | Oseltamivir 7 days |
|---|---|
| Also known as | 7-days postexposure chemoprophylaxis with oseltamivir |
| Sponsor | Centre of Postgraduate Medical Education |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) (PHASE1)
- Severe Influenza Trial of ARbidol (PHASE3)
- Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza (PHASE2, PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects (PHASE1)
- Catalysing the Containment of COVID-19 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oseltamivir 7 days CI brief — competitive landscape report
- Oseltamivir 7 days updates RSS · CI watch RSS
- Centre of Postgraduate Medical Education portfolio CI